Disclosure of transactions in own shares between 18/06/2019 and 21/06/2019

Corporate 03 December 2024 6 mins read

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

Corporate 18 November 2024 12 mins read

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Corporate 15 November 2024 12 mins read

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Corporate 23 October 2024 4 mins read

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

Corporate 14 October 2024 5 mins read

Ipsen receives its second Shingo Prize for operational excellence

Corporate 23 September 2024 8 mins read

Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease

Corporate 20 September 2024 8 mins read

Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade

Corporate 16 September 2024 9 mins read

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors

Corporate 15 September 2024 7 mins read

Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

Corporate 26 July 2024 12 mins read

Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases